PubRank

Peter A Jones

Author PubWeight™ 216.53‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002 12.33
2 Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004 11.46
3 A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011 11.33
4 Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006 8.46
5 Epigenetics in cancer. Carcinogenesis 2009 7.49
6 Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006 6.39
7 Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med 2008 4.41
8 Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A 2004 4.39
9 Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A 2008 4.20
10 Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002 3.89
11 Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012 3.65
12 Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 2002 3.61
13 DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009 3.56
14 The CpG island searcher: a new WWW resource. In Silico Biol 2003 3.42
15 Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004 3.23
16 Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010 3.16
17 Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 2007 3.15
18 DNA methylation and breast carcinogenesis. Oncogene 2002 3.03
19 Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res 2002 3.02
20 DNA methylation: the nuts and bolts of repression. J Cell Physiol 2007 3.00
21 The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009 2.83
22 Epigenetics and microRNAs. Pediatr Res 2007 2.52
23 DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 2012 2.45
24 Preferential response of cancer cells to zebularine. Cancer Cell 2004 2.39
25 Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol 2009 2.34
26 Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet 2010 2.27
27 Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A 2006 2.25
28 Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003 2.22
29 Polycomb-repressed genes have permissive enhancers that initiate reprogramming. Cell 2011 2.14
30 p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007 2.14
31 Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila) 2008 2.04
32 Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006 1.98
33 Epigenetic changes in cancer. APMIS 2007 1.96
34 Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. Genome Res 2012 1.95
35 Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res 2005 1.94
36 H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes. Mol Cell 2010 1.85
37 Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol Cancer Ther 2005 1.85
38 DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet 2011 1.83
39 DNA methylation and cellular reprogramming. Trends Cell Biol 2010 1.77
40 Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res 2002 1.71
41 Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004 1.69
42 Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2004 1.68
43 Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 2004 1.68
44 Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 2003 1.62
45 Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010 1.61
46 Preoperative sentinel node identification with ultrasound using microbubbles in patients with breast cancer. AJR Am J Roentgenol 2011 1.58
47 Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet 2011 1.56
48 OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. Proc Natl Acad Sci U S A 2011 1.51
49 Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genet 2006 1.48
50 Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014 1.47
51 Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 2010 1.47
52 Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol 2006 1.46
53 Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget 2013 1.44
54 MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly 2009 1.43
55 DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res 2008 1.42
56 Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005 1.41
57 Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 2007 1.40
58 Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007 1.40
59 Emergency Department utilisation: a natural experiment. N Z Med J 2009 1.39
60 Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells. Mol Cell Biol 2011 1.34
61 Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res 2002 1.32
62 DNA methylation and cancer. Prog Drug Res 2011 1.24
63 Chromatin, cancer and drug therapies. Mutat Res 2008 1.21
64 Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome. Mol Biol Evol 2003 1.20
65 Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer 2005 1.18
66 Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood 2011 1.17
67 Genome-wide nucleosome map and cytosine methylation levels of an ancient human genome. Genome Res 2013 1.12
68 Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res 2005 1.12
69 Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci 2005 1.11
70 Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res 2013 1.09
71 Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet 2012 1.07
72 Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One 2010 1.07
73 Analysis of individual remodeled nucleosomes reveals decreased histone-DNA contacts created by hSWI/SNF. Nucleic Acids Res 2009 1.07
74 Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE). Methods 2002 1.06
75 Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction. Methods 2002 1.06
76 RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res 2008 1.05
77 Identification and characterization of alternatively spliced variants of DNA methyltransferase 3a in mammalian cells. Gene 2002 1.04
78 Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids 2005 0.99
79 A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 2014 0.99
80 The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle 2009 0.94
81 S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther 2010 0.94
82 Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004 0.94
83 At the tipping point for epigenetic therapies in cancer. J Clin Invest 2014 0.94
84 Preoperative needle biopsy of sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound in patients with breast cancer. AJR Am J Roentgenol 2012 0.93
85 The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res., 8: 131-137, 2002, and H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res., 8: 188-191, 2002. Clin Cancer Res 2002 0.93
86 Methylation-sensitive single-molecule analysis of chromatin structure. Curr Protoc Mol Biol 2010 0.93
87 Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. Transl Oncol 2009 0.91
88 Diagnostic markers of urothelial cancer based on DNA methylation analysis. BMC Cancer 2013 0.90
89 Differentially methylated alleles in a distinct region of the human interleukin-1alpha promoter are associated with allele-specific expression of IL-1alpha in CD4+ T cells. Blood 2006 0.87
90 A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res 2012 0.87
91 SNF5 is an essential executor of epigenetic regulation during differentiation. PLoS Genet 2013 0.87
92 Meddling with methylation. Nat Cell Biol 2003 0.86
93 Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics 2011 0.86
94 Radiopaque coil insertion into breast cancers prior to neoadjuvant chemotherapy. Breast 2005 0.86
95 Patch clamp recording from enteric neurons in situ. Nat Protoc 2011 0.82
96 Reprogramming of the human intestinal epigenome by surgical tissue transposition. Genome Res 2014 0.80
97 Percutaneous removal of sentinel lymph nodes in a swine model using a breast lesion excision system and contrast-enhanced ultrasound. Eur Radiol 2011 0.79
98 Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine. J Med Chem 2008 0.79
99 Role of nucleosomes in mitotic bookmarking. Cell Cycle 2011 0.79
100 Establishment of active chromatin structure at enhancer elements by mixed-lineage leukemia 1 to initiate estrogen-dependent gene expression. Nucleic Acids Res 2013 0.78
101 Molecular targets and targeted therapies in bladder cancer management. World J Urol 2008 0.78
102 Lysine methyltransferase G9a is not required for DNMT3A/3B anchoring to methylated nucleosomes and maintenance of DNA methylation in somatic cells. Epigenetics Chromatin 2012 0.78
103 Alterations in deoxyribonucleic acid (DNA) methylation patterns of Calca, Timp3, Mmp2, and Igf2r are associated with chronic cystitis in a cyclophosphamide-induced mouse model. Urology 2013 0.78
104 The critique of sentinel node biopsy as an acceptable way of locally staging breast cancer. Breast 2007 0.75